US FDA recommends Lupin ‘assess its global manufacturing operations’

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Metamorworks)
(Image: Getty/Metamorworks)

Related tags: Lupin Pharmaceuticals, India, Warning letter

After an investigation last year, the FDA cites problems across multiple sites within the Lupin manufacturing network, raising questions about ‘management oversight and control’.

The US Food and Drug Administration (FDA) has made public​ a warning letter delivered to Lupin regarding inspections that took place between November 26 and December 5, 2018, at its Mandideep, India site.

The conclusions of the inspection saw the FDA highlight concerns over Lupin’s overall ability to maintain current good manufacturing practices (cGMP), mentioning that it had issued similar observations on its Goa and Indore facilities.

In the warning letter, the agency told Lupin, “These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs are inadequate. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products you manufacture conform to FDA requirements.”

In particular, at Lupin’s Mandideep facility, the agency narrowed down on three violations: the failure to fully investigate unexpected discrepancies or failure of batches; the failure to establish adequate written procedures for production and process control; and, the failure to clean, maintain and sanitize/sterilize equipment.

On the latter finding, the agency noted that its inspectors discovered a tablet press labelled as cleaned, despite there being ‘unknown residues’ on product contact surfaces.

Last month​, Lupin acknowledged the delivery of the warning letter and stated, “The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues for operations of this facility.”

The company continued to say that it is working with the FDA to resolve the issues.

Earlier this year, the company received a Form 483​ from the agency, after human hair was discovered contaminating product, and, at the end of the previous year, a number of observations​ were noted regarding the same Mandideep site.

At the time of writing, shares in Lupin were down 8% from prior to the publication of the warning letter.

Related news

Show more

Related products

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us


View more